Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Breast Neoplasms Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Early Detection of Cancer Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Colonic Neoplasms Medicine & Life Sciences
Phosphatidylinositol 3-Kinase Medicine & Life Sciences
Patient Navigation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ERþ/HER2 mutant breast cancer

Croessmann, S., Formisano, L., Kinch, L. N., Gonzalez-Ericsson, P. I., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E. H., Cristofanilli, M., He, J., Cutler, R. E., Lalani, A. S., Miller, V. A., Lanman, R. B., Grishin, N. V. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 277-289 13 p.

Research output: Contribution to journalArticle

Breast Neoplasms
MCF-7 Cells
Mutation
Estrogens
Estrogen Receptor Modulators

Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C. L. & Neven, P., Jan 1 2019, (Accepted/In press) In : Clinical Drug Investigation.

Research output: Contribution to journalArticle

Consultants
Breast Neoplasms
Pharmaceutical Preparations
fulvestrant

Erratum: Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer (eLife (2016) 5 PII: e44851)

Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K. & 26 othersMoon, M., Prudente, R., Bischoff, E., Lee, K. J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C. & Hager, J. H., Jan 7 2019, In : eLife. 8

Research output: Contribution to journalComment/debate

Estrogen Receptors
Medicine
Breast Neoplasms
3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid